Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
28
6
2019
medline:
29
1
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
A recent study demonstrated remarkable discrepancy between the relapse-free survival (RFS) and overall survival (OS) after pulmonary metastasectomy (PM) in the current era. As the RFS may not be a suitable parameter after PM, a more suitable parameter is needed for PM as a surrogate marker for OS. A total of 134 consecutive patients who underwent PM were retrospectively analyzed. In the present study, we introduced a new endpoint, time to local treatment failure (TLTF). This endpoint was defined as the time interval between the first PM and the first untreatable recurrence by local treatment with curative intent or death due to any cause. We analyzed the correlation between the RFS and OS and between the TLTF and OS to validate whether or not the TLTF is a better parameter than the RFS after PM. Thus far, 78 patients have experienced relapse. Of these, 37 patients (47%) underwent local therapy with curative intent, 29 of whom are alive without local treatment failure. The 5-year OS, RFS and TLTF were 70.9%, 36.5%, and 57.6%, respectively. The concordance proportions for the RFS and OS and for the TLTF and OS were 0.634 and 0.851 for all patients, respectively. The Spearman's rank correlation coefficient for the RFS and OS was 0.639, while that for the TLTF and OS was 0.875. The TLTF may be a good surrogate parameter for the OS after PM in the current era.
Sections du résumé
BACKGROUND
A recent study demonstrated remarkable discrepancy between the relapse-free survival (RFS) and overall survival (OS) after pulmonary metastasectomy (PM) in the current era. As the RFS may not be a suitable parameter after PM, a more suitable parameter is needed for PM as a surrogate marker for OS.
METHODS
A total of 134 consecutive patients who underwent PM were retrospectively analyzed. In the present study, we introduced a new endpoint, time to local treatment failure (TLTF). This endpoint was defined as the time interval between the first PM and the first untreatable recurrence by local treatment with curative intent or death due to any cause. We analyzed the correlation between the RFS and OS and between the TLTF and OS to validate whether or not the TLTF is a better parameter than the RFS after PM.
RESULTS
Thus far, 78 patients have experienced relapse. Of these, 37 patients (47%) underwent local therapy with curative intent, 29 of whom are alive without local treatment failure. The 5-year OS, RFS and TLTF were 70.9%, 36.5%, and 57.6%, respectively. The concordance proportions for the RFS and OS and for the TLTF and OS were 0.634 and 0.851 for all patients, respectively. The Spearman's rank correlation coefficient for the RFS and OS was 0.639, while that for the TLTF and OS was 0.875.
CONCLUSIONS
The TLTF may be a good surrogate parameter for the OS after PM in the current era.
Identifiants
pubmed: 31243525
doi: 10.1007/s00268-019-05071-2
pii: 10.1007/s00268-019-05071-2
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2640-2646Références
J Thorac Cardiovasc Surg. 2015 May;149(5):1249-52
pubmed: 25802136
BMJ Support Palliat Care. 2015 Dec;5(4):390-8
pubmed: 26586684
Ann Thorac Surg. 2017 Dec;104(6):1837-1845
pubmed: 29074153
Surg Today. 2014 Apr;44(4):646-52
pubmed: 23589058
Gan To Kagaku Ryoho. 2011 Nov;38(12):2310-2
pubmed: 22202365
Gen Thorac Cardiovasc Surg. 2015 Jun;63(6):320-30
pubmed: 25836329
World J Gastroenterol. 2014 Jan 28;20(4):988-96
pubmed: 24574771
J Thorac Cardiovasc Surg. 1965 Mar;49:357-63
pubmed: 14265951
Expert Opin Investig Drugs. 2019 Jan;28(1):39-50
pubmed: 30513001
Surg Today. 2017 Sep;47(9):1111-1118
pubmed: 28205021
Eur Urol. 2018 Apr;73(4):543-557
pubmed: 29122377
Interact Cardiovasc Thorac Surg. 2017 Mar 1;24(3):418-424
pubmed: 28040757
Ann Thorac Surg. 2011 Aug;92(2):449-53
pubmed: 21801905
Am J Surg. 2011 Oct;202(4):419-26
pubmed: 21824604
Eur J Cardiothorac Surg. 2011 Feb;39(2):167-72
pubmed: 20591686
J Clin Oncol. 2018 Oct 29;:JCO2018792259
pubmed: 30372384
J Thorac Oncol. 2017 Sep;12(9):1442-1445
pubmed: 28576747
Int J Clin Oncol. 2005 Apr;10(2):81-5
pubmed: 15864692
Interact Cardiovasc Thorac Surg. 2010 Jul;11(1):60-4
pubmed: 20395251
Ann Surg Oncol. 2014 Jun;21(6):1817-24
pubmed: 24499828